Thanks to intensive insulin therapy protocols since diagnosis, reproducible long-lasting and rapid-acting human insulin preparations and advances in technological instruments for T1DM management, clinically evident microangiopathy in children and adolescents is almost rarely encountered. This evidence concerns the gene INS and type 1 diabetes mellitus.